FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Authority Hl7

42,405 resources

Type: Text:

By Version

By Realm

 

Start Prev Rows 25600 - 25800 Next

PackageVersionIdentityName/TitleStatusFMMWGDateRealm
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.828Antimycobacterialsactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.829Beta_lactamaseactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.830Cyclic lipopeptidesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.831Lincosamidesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.832Macrolidesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.833Amphenicolactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.834Oxazolidinonesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.835Fluoroquinolonesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.836Sulfonamidesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.837Tetracyclinesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.838Phosphonicsactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.839Pleuromutilinactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.840Streptograminsactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.841Lipoglycopeptidesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.842Nitroimidazolesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.843PIM_Hyd_Bus_Mir_Traactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.844Nitrofuransactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.845Rifamycinsactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.846Glycylcyclineactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.847Pyrimidinesactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.849Antibiotics oral and parenteralactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.850Medications_hyperkalemiaactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.852Hyperkalemia_ICD10active2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.853Hyperkalemia_SCTactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.854Hyperkalemia Conditionsactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.855Medications_Chronic Hyperkalemiaactive2024-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.858PIM_Alpha_Blockers_2active2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.860PIM_Ambulatory_Visits_CPTsactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.862PIM_Ambulatory_Visits_SNOMEDactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.863PIM_Thyroid_Stimulating_Hormone_(TSH)active2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.864PIM_Triiodothyronine_(T3)active2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.865PIM_Thyroxine_(T4)active2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.866PIM_Magnesium_LOINCactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.867PIM_BMP_CMP_LOINCactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.868PIM_URIC_ACID_LOINCactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.869PIM_Migraine_Medicationsactive2025-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.870PIM_Triptansactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.871ICS_SABA Relieveractive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.873PIM_Asthma_COPD_Medsactive2025-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.874PIM_Lipid_Panel_CPTsactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.875PIM_Hepatic_Function_Panel_CPTsactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.876Alpha Glucosidase Allergy Intoleranceactive2025-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.877Inflammatory bowel disease I10active2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.878Inflammatory bowel disease SCTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.879Inflammatory bowel diseaseactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.880Gastrointestinal obstruction SCTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.881Gastrointestinal obstruction I10active2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.882Gastrointestinal obstructionactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.883DPP4i Allergy Intoleranceactive2025-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.884Multiple endocrine neoplasia type 2 (MEN II) SCTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.885Multiple endocrine neoplasia type 2 (MEN II) I10active2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.886Multiple endocrine neoplasia type 2 (MEN II)active2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.887Gastroparesis SCTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.888Gastroparesis I10active2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.889Gastroparesisactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.890Meglitinide Allergy Intoleranceactive2025-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.891Sulfonylurea Allergy Intoleranceactive2025-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.892Peripheral edema I10active2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.893Peripheral edema SCTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.894Peripheral edemaactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.895TZD Allergy Intoleranceactive2025-05us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.896PIM_Beta_Blockersactive2024-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.897PIM_CCB_DHPsactive2024-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.898PIM_Loop_Diureticsactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.899PIM_Inhaled_Corticosteroids_(ICS)active2025-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.9ACE inhibitorsactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.90ASCVD I10active2023-09us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.900PIM_Leukotrienesactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.901OIA_Asthma_COPD_Meds_Inhalersactive2025-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.902OIA_Asthma_COPD_Meds_Nebulizersactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.903OIA_Asthma_COPD_Meds_Oralactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.904OIA_GLP1_Injectablesactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.905OIA_Insulin_Injectablesactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.906OIA_Oral_Hypoglycemicsactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.907OIA_DM1_DM2_Medsactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.908Medium Dose ICS Formoterolactive2024-05us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.909High Dose ICS Formoterolactive2024-05us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.910CKD stage5OrESRD I10active2024-05us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.911CKD stage5OrESRD SCTactive2024-05us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.912CKD stage5OrESRDactive2024-05us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.914Anxiety_I10active2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.915Anxiety_SCTactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.916Anxietyactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.918Stress_SCTactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.919Stress_I10active2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.920Stressactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.921PBH_Anxiety_SCTactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.922PBH_Depression_SCTactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.923PBH_Stress_SCTactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.924PBH_Insomnia_SCTactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.925PIM_CMP_CPTsactive2024-06us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.926Canagliflozin medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.927Empagliflozin medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.928Dapagliflozin medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.929Ertugliflozin medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.930Dulaglutide medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.931Liraglutide medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.932Semaglutide SC medsactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.933T2DM meds benefitting ASCVDactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.934T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/minactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.935T2DM meds benefitting CKD stage 5active2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.936T2DM meds benefitting HF with eGFR >= 20 mL/minactive2024-07us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.938Crohn disease SCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.939Crohn disease I10active2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.940Crohn diseaseactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.941Celiac disease SCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.942Celiac disease I10active2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.943Celiac diseaseactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.944OIA_Bisoprololactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.945OIA_PVD_ICD10active2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.946Vibration Controlled Transient Elastography (VCTE)active2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.947OIA_Antihypertensive_Medicationsactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.950OIA_CAD_ICD10active2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.951OIA_DM_ICD10active2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.952OIA_Creatinine_Levels_LOINCactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.953OIA_DM_SNOMEDCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.954OIA_CAD_SNOMEDCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.955OIA_PVD_SNOMEDCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.956OIA_DM_ICD10_SNOMEDCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.957OIA_CAD_ICD10_SNOMEDCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.958OIA_PVD_ICD10_SNOMEDCTactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.959ACEi for HFrEFactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.960ARB for HFrEFactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.961OIA_AntiHTN_Meds_Inclusion_Listactive2024-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.962OIA_Thiazide_Diureticsactive2024-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.963OIA_RFs_ACS_ICD10active2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.964OIA_RFs_ACS_SNOMEDactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.965OIA_RFs_ACS__ICD10_SNOMEDactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.966OIA_Aortic_Calcifications_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.967OIA_Aortic_Calcifications_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.968OIA_Aortic_Calcifications_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.969OIA_Microalbuminactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.97Sulfonylurea AllergyIntolerance SCTactive2023-09us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.970OIA_LDL_Cholesterolactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.971Pioglitazoneactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.972MASLD I10active2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.973MASLD SCTactive2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.975OIA_Sulfonylureasactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.978OIA_RFs_ASCVD_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.979OIA_RFs_ASCVD_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.98BMI LOINCactive2024-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.980OIA_RFs_ASCVD_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.981OIA_TIA_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.982OIA_TIA_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.983OIA_TIA_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.984OIA_Angina_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.985OIA_Angina_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.987OIA_Angina_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.988OIA_Ischemic_Hemorrhagic_Stroke_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.989OIA_Ischemic_Hemorrhagic_Stroke_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.990OIA_Ischemic_Hemorrhagic_Stroke_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.991OIA_Myocardial_Infarction_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.992OIA_Myocardial_Infarction_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.993OIA_Myocardial_Infarction_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.995OIA_PAD_ICD10active2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.996OIA_PAD_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.997OIA_PAD_ICD10_SNOMEDactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1078.998OIA_Coronary_Arterial_Revascularizationactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1080.5Contact or Office Visitactive2022-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1080.6Contact or Office Visitactive2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1080.7Contact or Office Visitactive2022-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.10Nutrition Diagnosis SNOMED CTactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.101Hospice Statusactive2024-10us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.14Vitamin Mineral Supplement and Bioactive Substance Management SNOMED CTactive2020-08us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.17Pediatric Enteral Formulas SNOMED CTactive2021-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.18Modified Amino Acid Formulas SNOMED CTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.19Nutrition Counseling Approach and Strategies SNOMED CTactive2020-09us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.20Enteral Nutrition Management SNOMED CTactive2020-09us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.21Nutrition Assessmentactive2024-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.25Nutritional Status Severely Malnourishedactive2016-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.30Malnutrition Risk Screeningactive2015-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.31Malnutrition At Riskactive2015-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.32Malnutrition Risk Screeningactive2016-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.34Malnutrition Screening Finding of Not At Risk Resultactive2024-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.35Malnutrition Screening Not at Riskactive2015-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.38Malnutrition Screening Finding of At Risk Resultactive2025-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.39Malnutrition Risk Screeningactive2016-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.40Malnutrition Risk Screeningactive2022-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.41Nutritional Status Severely Malnourishedactive2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.42Nutrition Assessment Status Finding of Severely Malnourishedactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.43Nutrition Assessment Status Finding of Severely Malnourishedactive2024-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.44Nutrition Assessment Status Finding of Moderately Malnourishedactive2024-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.45Nutritional Status Moderately Malnourishedactive2015-11us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.46Nutritional Status Moderately Malnourishedactive2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.47Nutrition Assessment Status Finding of Moderately Malnourishedactive2024-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.48Nutrition Assessment Status Finding of Well Nourished or Not Malnourished or Mildly Malnourishedactive2024-01us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.49Nutrition Focused Physical Findings Groupingactive2022-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.5Adult Enteral Formulas SNOMED CTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.50Enteral Nutrition Composition SNOMED CTactive2024-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.51Enteral Nutrition Composition Groupingactive2022-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.52Parenteral Nutrition Management SNOMED CTactive2020-09us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.53Malnutrition Diagnosisactive2024-12us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.54Malnutrition Diagnosisactive2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.55Malnutrition Diagnosisactive2022-03us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.56Malnutrition Diagnosisactive2016-09us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.59Diet Item Groupingactive2018-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.60Edible Substancesactive2021-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.61Feeding Device SNOMED CTactive2021-04us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.65Nutrition Recommendation Groupingactive2025-02us
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1095.7Modular Nutrition Formulas SNOMED CTactive2021-04us